The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures

Journal of Musculoskeletal Neuronal Interactions

Volumn 5, Issue 3, 2005, Pages 273-284

  Schacht, E ^a   Richy, F ^b   Reginster, Jean Yves ^b  

^a BALGRIST UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Age related osteoporosis; Alfacalcidol; Falls; Fractures; Glucocorticoid inflammation induced osteoporosis

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; CALCITRIOL; CALCIUM; CORTICOSTEROID; CYCLOSPORIN A; ETIDRONIC ACID; GLUCOCORTICOID; PARATHYROID HORMONE; PLACEBO; PREDNISOLONE; SEX HORMONE; VITAMIN D DERIVATIVE;

BONE REMODELING; BONE STRENGTH; BONE TURNOVER; CALCIUM HOMEOSTASIS; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; FALLING; GRAFT REJECTION; HIGH RISK PATIENT; HORMONE BLOOD LEVEL; HORMONE DEFICIENCY; HORMONE SYNTHESIS; HUMAN; HYPERCALCEMIA; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LIVER METABOLISM; META ANALYSIS; MUSCLE ATROPHY; MUSCLE METABOLISM; MUSCLE STRENGTH; NONHUMAN; ORGAN TRANSPLANTATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PATHOGENESIS; POSTMENOPAUSE OSTEOPOROSIS; RECEPTOR AFFINITY; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK REDUCTION; VERTEBRA FRACTURE; VITAMIN D DEFICIENCY;

ACCIDENTAL FALLS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCITRIOL; FRACTURES, BONE; HUMANS; HYDROXYCHOLECALCIFEROLS; MUSCLE, SKELETAL; OSTEOPOROSIS; VITAMIN D DEFICIENCY;

EID: 28044460306     PISSN: 11087161     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Ford AB. Reducing the threat of hip fracture. AM J Public Health 1989; 79:269-270.
2. Mosekilde L. Vertebral structure and strength in vivo and in vitro. Calcif Tissue Int 1993; 53:S121-S126.
3. Runge M, Schacht E. Multifactorial pathogenesis of falls as a basis for multifactorial interventions. J Musculoskel Neuronal Interact; 2005 (in press).
4. Guralnik JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med 1995; 332:556-561.
5. Ferrucci L, Penninx BW, Leveille SG, Corti MC, Pahor M, Wallace R, Harris TB, Havlik RJ, Guralnik JM. Characteristics of non-disabled older persons who perform poorly in objective tests of lower extremity function. J Am Geriatr Soc 2000; 48:1102-1110.
6. Greiwe JS, Cheng B, Rubin DC, Yarasheski KE, Semenkovich CF. Resistance exercise decreases skeletal muscle tumor necrosis factor a in frail elderly humans. FASEB J 2001; 15:475-482.
7. Nordin BEC, Need AG, Morris, HA, Horowitz M. The special role of "hormonal" forms of vitamin D in the treatment of osteoporosis. Calcif Tissue Int 1999; 65:307-310.
8. Lau KHW, Baylink DJ. Vitamin D therapy of osteoporosis: plain vitamin D therapy versus active vitamin D analog (D-hormone) therapy. Calcif Tissue Int 1999; 65:295-306.
9. 3(D-hormone) deficiency/resistance with D-hormone and analogs. Osteologie 2001; 10:28-39.
10. Schacht E. Rationale for treatment of involutional osteoporosis in women and for prevention and treatment of corticosteroid-induced osteoporosis with alfacalcidol. Calcif Tissue Int 1999; 65:317-327.
11. Shiraishi A, Takeda S, Masaki T, Higuchi Y, Uchiama Y, Kubodera N, Sato K, Ikeda K, Nakamura T, Matsumoto T, Ogata E. Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct action from estrogen. J Bone Miner Res 2000; 15:770-779.
12. Shiraishi A, Higashi S, Ohkawa H, Kubodera N, Hirasawa T, Ezawa I, Ikeda K, Ogata E. The advantage of alfacalcidol over vitamin D in the treatment of osteoporosis. Calcif Tissue Int 1999; 65:311-316.
13. 3 on bone loss by ovariectomy in aged rats. Jpn J Pharmacol 2002; 89:255-266.
14. Bischoff HA, Borchers M, Gudat F, Duermueller U, Theiler R, Stähelin HB, Dick W. In situ detection of 1,25-dihydroxyvitamin D receptor in human skeletal muscle tissue. Histochem 2001; 33:19-24.
15. Bischoff HA, Stähelin HB, Urscheler N, Ehrsam R, Vontheim R, Perrig-Chiello P, Tyndall A, Theiler R. Muscle strength in the elderly: its relation to vitamin D metabolites. Arch Phys Med Rehabil 1999; 80:54-58.
16. Sörensen OH, Lund BI, Saltin B, Lund BJ, Andersen RB, Hjorth L, Melson F, Mosekilde F. Myopathy in bone loss of ageing: improvement by treatment with 1-alpha-hydroxycholecalciferol and calcium. Clinical Science 1979; 56:157-161.
17. Verhaar HJJ, Samson MM, Jansen PAF, de Vreede PL, Manten JW, Duursma SA. Muscle strength, functional mobility and vitamin D in older women. Aging Clin Exp Res 2000; 12:455-460.
18. Scharla SH, Schacht E, Bawey S, Kamilli I, Holle D, Lempert UG. Pleiotropic effects of alfacalcidol in elderly patients with rheumatoid arthritis, arthritis + rheuma 2003; 23:268-274.
19. Gallagher JC, Fowler SE, Detter JR, Sherman SS. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. J Clin Endocrinol Metab 2001; 86:3618-3628.
20. Gallagher JC. The effects of calcitriol on falls and fractures and physical performance tests. J Steroid Biochem Mol Biol 2004; 89-90:497-501.
21. Dukas L, Bischoff HA, Lindpaintner LS, Schacht E, Birkner-Binder D, Damm TN, Thalmann B, Stähelin HB. Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. J Am Geriatr Soc 2004; 52:230-236.
22. 3 and calcium supplementation. Stroke 1997; 28:736-739.
23. 3 in elderly patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999; 66:64-68.
24. Wong M. Raloxifene does not affect neuromuscular-related risk factors for falling or the incidence of falls in postmenopausal women with osteoporosis. J Am Geriatr Soc 2000; 48:S44.
25. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001; 344;333-340.
26. Wolf SL, Barnhart HX, Kutner NG, McNeely E, Coogler C, Xu T. Reducing frailty and falls in older persons: an investigation of Tai Chi and computerized balance training. Atlanta FICSIT Group. Frailty and Injuries: Co-operative Studies of Intervention Techniques. J Am Geriatr Soc 1996; 44:489-97.
27. 3. JBMR 1992; 10:50:184-188.
28. 3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int 1994; 54:370-376.
29. Tilyard MW, Spears GF, Thomson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 1992; 326:357-362.
30. Tanizawa T, Imura K, Ishii Y, Nishida S, Takano Y, Mashiba T, Endo N, Takahashi HE. Treatment with active vitamin D metabolites and concurrent treatments in the prevention of hip fractures: a retrospective study. Osteoporos Int 1999; 9:163-170.
31. Papadimitropoulos E, Wells G, Shea B, Gillespie W, Weaver B, Zytaruk N, Cranney A, Adachi J, Tugwell P, Josse R, Greenwood C, Guyatt G. The Osteoporosis Methodology Group, and the Osteoporosis Research Advisory Group. Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 2002; 23:560-569.
32. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C. The Osteoporosis Methodology Group, and the Osteoporosis Research Advisory Group. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocrine Reviews 2002; 23:570-578.
33. Richy F, Ethgen O, Bruyere O, Reginster J-Y. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 2004; 15:301-310.
34. Godschalk M, Levy RJ, Downs RW. Glucocorticoids decrease vitamin D receptor numbers and gene expression in human osteosarcoma cells. J Bone Miner Res 1992; 7:21-27.
35. 3 1α-hydroxylase promoter. Mol Endocrinol 2004; 18:2440-2450.
36. Oelzner P, Muller A, Deschner F, Huller M, Abendroth K, Hein G, Stein G. Relationship between disease activity and serum levels of vitamin D metabolites and PTH in rheumatoid arthritis. Calcif Tissue Int 1998; 62:193-198.
37. 3 prevents the decrease of bone mineral appositional rate in rats with inflammation-mediated osteopenia (IMO). Bone Miner 1989; 7:149-158.
38. DeLuca HF, Cantorna MT. Vitamin D: its role and uses in immunology. FASEB J 2001; 15:2579-2585.
39. 3 analogs as immunomodulatory agents. Trends Mol Med 2002; 8:174-179.
40. 3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-β1 and IL-4. J Immunol 1998; 160:5314-5319.
41. Cantorna MT, Hayes CE, DeLuca HF. 1,25-dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr 1998; 128:68-72.
42. 3 in rheumatoid arthritis patients. Rheum Eur 1996; 25:33.
43. 3 - a hormone with immunomodulatory properties. Z Rheumatol 2000; 59:24-27.
44. Adachi JD, Bensen WG, Bianchi F, Cividino A, Pillersdorf S, Sebaldt RJ, Tugwell P, Gordon M, Steele M, Webber C, Goldsmith CH. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year follow up. J Rheumatol 1996; 23:995-1000.
45. Reginster JY, Kuntz D, Verdickt W, Wouters M, Guillevin L, Menkes CJ, Nielsen K. Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporos Int 1999; 9:75-81.
46. Lakatos P, Nagy Z, Kiss L, Horvath C, Takacs I, Foldes J, Speer G, Bossanyi A. Prevention of corticosteroid-induced osteoporosis by alfacalcidol. Z Rheumatol 2000; 59:48-52.
47. Van Cleemput J, Daenen W, Geusens P, Dequeker J, van de Werf F, VanHaecke J. Prevention of bone loss in cardiac transplant recipients. Transplantation 1996; 61:1495-1499.
48. Sambrook PN, Henderson NK, Keogh A, Macdonald P, Glanville A, Spratt P, Bergin P, Ebeling P, Eisman J. Effect of calcitriol on bone loss after cardiac or lung transplantation. J Bone Miner Res 2000; 15:1818-1824.
49. Shane E, Addesso V, Namerow P, McMahon D, Lo S, Staron R, Zucker M, Pardi S, Maybaum S, Mancini D. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med 2004; 350:767-776.
50. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 2001; 44:1496-1503.
51. Ringe JD, Dorst A, Faber H, Schacht E, Rahlfs VW. Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis. Rheumatol Int 2004; 24:63-70.
52. Van Staa TP, Leufkens HGM, Abenhaim A, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15:993-1000.
53. 3 analog and a bisphosphonate prevents experimental autoimmune encephalomyelitis and preserves bone. Bone 2003; 32:397-404.
54. Shibata T, Shira-Ishi A, Sato T, Masaki T, Sasaki A, Masuda Y, Hishiya A, Ishikura N, Higashi S, Uchida Y, Saito M, Ito M, Ogata E, Watanabe K, Ikeda K. Vitamin D hormone inhibits osteoclastogenesis in vivo by decreasing the pool of osteoclast precursors in bone marrow. J Bone Miner Res 2002; 17:622-629.
55. Sambrook PN, Kotowicz M, Nash P, Styles CB, Naganathan V, Henderson-Briffa KN, Eisman JA, Nicholson GC. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium and alendronate plus calcium. J Bone Miner Res 2003; 18:919-924.
56. Cappola AR, Xue QL, Ferrucci L, Guralnik JM, Volpato S, Fried LP. Insulin-like growth factor I and interleukin-6 contribute synergistically to disability and mortality in older women. J Clin Endocrinol Metab 2003; 88:2019-2025.
57. Endo I, Inoue D, Mitsui T, Umaki Y, Akaike M, Yoshizawa T, Kato S, Matsumoto T. Deletion of vitamin D receptor gene in mice results in abnormal skeletal muscle development with deregulated expression of myoregulatory transcription factors. Endocrinology 2003; 144:5138-5144.
58. Boland R. Role of vitamin D in skeletal muscle function. Endocr Rev 1986; 784:434-448.
59. Bischoff-Ferrari HA, Borchers M, Gudat F, Dürmüller U, Stähelin HB, Dick W. Vitamin D receptor expression in human muscle tissue decreases with age. J Bone Miner Res 2004; 19:265-269.
60. Dukas L, Schacht E, Bischoff HA. Better functional mobility in community dwelling elderly is related to D-hormone serum levels and to a daily calcium intake. Accepted for publication in Journal on Nutrition, Health and Aging 2005.
61. Dukas L, Schacht E, Mazor Z, Stähelin HB. Treatment with alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of <65 ml/min. Osteoporos Int 2005; 16:198-203.
62. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Staehelin HB, Bazemore MG, Zee RY, Wong JB. Effect of vitamin D on falls. JAMA 2004; 291:1999-2006.
63. Richy F, Schacht E, Bruyère O, Ethgen O, Gourlay M, Reginster JY. Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis. Calcif Tissue Int 2005; 76:176-186.
64. Ringe JD, Schacht E. Prevention and therapy of osteoporosis: the respective roles of plain vitamin D and alfacalcidol. Rheumatol Int 2004; 24:189-197.
65. Gayan-Ramirez G, Vanderhoydone F, Verhoeven G, Decramer M. Acute treatment with corticosteroids decreases IGF-I and IGF-2 expression in the rat diaphragm and gastrocnemius. Am J Respir Crit Care Med 1999; 159:283-289.
66. Argiles JM, Alvarez B, Carbo N, Busquets S, Van Royen M, Lopez-Soriano FJ. The divergent effects of tumour necrosis factor-alpha on skeletal muscle: implications in wasting. Eur Cytokine Netw 2000; 11:552-559.
67. Grounds MD. Reasons for the degeneration of ageing skeletal muscle: a central role for IGF-1 signalling. Biogerontology 2002; 3:19-24.
68. Smith H, Anderson F, Raphael H, Crozier S, Cooper C. Effect of annual intramuscular vitamin D supplementation on fracture risk: population-based, randomised, double-blind, placebo-controlled trial. Osteoporos Int 2004; 15:S8.
69. Ma K, Mallidis C, Bhasin S, Mahabadi V, Artaza J, Gonzalez-Cadavid N, Arias J, Salehian. Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. Am J Physiol Endocrinol Metab 2003; 285:363-371.
70. Briffa NK, Keogh AM, Sambrook PN, Eisman JA. Reduction of immunosuppressant therapy requirement in heart transplantation by calcitriol. Transplantation 2003; 75:2133-2134.
71. de Nijs RNJ, Jacobs JWG, Algra A, Lems WF, Bijlsma JWJ. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int 2004;15:589-602.
72. Walsmith J, Abad L, Kehayias J, Roubenhoff R. Tumor necrosis factor-α production is associated with less body cell mass in women with rheumatoid arthritis. J Rheumatol 2004; 31:23-29.
73. 3 on the formation and function of osteoclastic cells. Calcif Tissue Int 1993; 52:255-260.
74. Seino Y, Ishizuka S, Shima M, Tanaka H. Vitamin D in bone formation. Osteoporos Int 1993; 3:196-198.
75. van Driel M, Pols HAP, van Leeuwen JPTM. Osteoblast differentiation and control by vitamin D and vitamin D metabolites. Curr Pharm Des 2004; 10:2535-2555.
76. 3 on bone metabolism in parathyroidectomized rats with continuous PTH infusion. Osteoporos Int 1997; 7(Suppl.2):35.
77. 3 in Japan. Aktuel Rheumatol 1994; 19(Suppl.):27-30.